“So we would expect to see continued strong uptake through 2025. And as we said, with the ramp back half of this year.”

In context

“, recall those 2 payers represent over 80% of the covered lives in this category. And as expected, the majority have 1 step edit post generic. We're also making very good progress with commercial payers. The feedback over the last several months has been very positive. There's been a lot of enthusiasm around the efficacy and safety profile. I'm also pleased with the number of trialists that we're seeing since launch, and we have an opportunity to further expand and increase adoption with roughly 30,000 psychiatrists. So as you said, this is the first new mechanism of action in decades in the treatment of schizophrenia. And so we're out with our teams educating customers on Cobenpi's differentiated profile and we're breaking reflexive prescribing habits, and that's going to take some time. So we would expect to see continued strong uptake through 2025. And as we said, with the ramp back half of this year. But taken together, we are really pleased with what we're seeing so far, and we plan to make this a very big product for the company over time. Christopher Boerner: Thanks, Adam. And Chris, with respect to the second part of your question on the cost program, let me say a few things. First, as you think about this cost program keep in mind that our focus as a company continues to be on investing for growth. That's investing in the products that we have today, investing in the pipeline, both the late-stage pipeline as well as promising early areas of science. And maybe just give you quick vignettes on that. We plan to initiate 7 Phase III programs starting this year on Coben, clearly illustrating that we'll continue to invest in our pipeline. And then Adam can speak to this, but we made si”